Literature DB >> 25394368

Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer.

Yukihiko Hiroshima1, Ali A Maawy, Matthew H G Katz, Jason B Fleming, Michael Bouvet, Itaru Endo, Robert M Hoffman.   

Abstract

BACKGROUND AND OBJECTIVES: Patient-derived orthotopic xenograft (PDOX) nude-mouse models replicate the behavior of clinical cancer, including metastasis. The objective of the study was to determine the efficacy of zoledronic acid (ZA) on metastasis of a patient-derived orthotopic xenograft (PDOX) nude-mouse model of pancreatic cancer.
METHODS: In the present study, we examined the efficacy of ZA on pancreatic cancer growth and metastasis in a PDOX nude-mouse model.
RESULTS: ZA monotherapy did not significantly suppress primary tumor growth. However, the primary tumor weight of gemcitabine (GEM) and combination GEM + ZA-treated mice was significantly decreased compared to the control group (GEM: P = 0.003; GEM + ZA: P = 0.002). The primary tumor weight of GEM + ZA-treated mice was significantly decreased compared to GEM-treated mice (P = 0.016). The metastasis weight decreased in ZA- or GEM-treated mice compared to the control group (ZA: P = 0.009; GEM: P = 0.007. No metastasis was detected in combination GEM + ZA-treated mice compared to the control group (GEM + ZA; P = 0.005).
CONCLUSIONS: The results of the present study indicate that ZA can selectively target metastasis in a pancreatic cancer PDOX model and that the combination of ZA and GEM should be evaluated clinically in the near future for this highly treatment-resistant disease.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  PDOX; combination; gemcitabine; nude mouse; orthotopic; pancreatic cancer; zoledronic acid

Mesh:

Substances:

Year:  2014        PMID: 25394368     DOI: 10.1002/jso.23816

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  41 in total

Review 1.  Targeting Rac and Cdc42 GTPases in Cancer.

Authors:  María Del Mar Maldonado; Suranganie Dharmawardhane
Journal:  Cancer Res       Date:  2018-06-01       Impact factor: 12.701

2.  Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.

Authors:  Kei Kawaguchi; Kentaro Miyake; Qinghong Han; Shukuan Li; Yuying Tan; Kentaro Igarashi; Thinzar M Lwin; Takashi Higuchi; Tasuku Kiyuna; Masuyo Miyake; Hiromichi Oshiro; Michael Bouvet; Michiaki Unno; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-05-21       Impact factor: 4.534

3.  Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.

Authors:  Kei Kawaguchi; Qinghong Han; Shukuan Li; Yuying Tan; Kentaro Igarashi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Bartosz Chmielowski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Arun S Singh; Mark A Eckardt; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-03-19       Impact factor: 4.534

4.  Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel.

Authors:  Takashi Murakami; Takuya Murata; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Igarashi; Ho Kyoung Hwang; Yukihiko Hiroshima; Chihiro Hozumi; Shin Komatsu; Takashi Kikuchi; Thinzar M Lwin; Jonathan C Delong; Kentaro Miyake; Yong Zhang; Kuniya Tanaka; Michael Bouvet; Itaru Endo; Robert M Hoffman
Journal:  Anticancer Res       Date:  2017-01       Impact factor: 2.480

5.  Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.

Authors:  Kei Kawaguchi; Kentaro Igarashi; Takashi Murakami; Tasuku Kiyuna; Scott D Nelson; Sarah M Dry; Yunfeng Li; Tara A Russell; Arun S Singh; Bartosz Chmielowski; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2017-04-20       Impact factor: 4.534

6.  Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Takashi Murakami; Tasuku Kiyuna; Kentaro Miyake; Scott D Nelson; Sarah M Dry; Yunfeng Li; Jane Yanagawa; Tara A Russell; Arun S Singh; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Hiroyuki Tsuchiya; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2017-05-11       Impact factor: 4.534

7.  Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and Pathology.

Authors:  Michaël Noë; Neda Rezaee; Kaushal Asrani; Michael Skaro; Vincent P Groot; Pei-Hsun Wu; Matthew T Olson; Seung-Mo Hong; Sung Joo Kim; Matthew J Weiss; Christopher L Wolfgang; Martin A Makary; Jin He; John L Cameron; Denis Wirtz; Nicholas J Roberts; G Johan A Offerhaus; Lodewijk A A Brosens; Laura D Wood; Ralph H Hruban
Journal:  Am J Pathol       Date:  2018-04-22       Impact factor: 4.307

8.  The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago.

Authors:  Takashi Murakami; Tasuku Kiyuna; Kei Kawaguchi; Kentaro Igarashi; Arun S Singh; Yukihiko Hiroshima; Yong Zhang; Ming Zhao; Kentaro Miyake; Scott D Nelson; Sarah M Dry; Yunfeng Li; Jonathan C DeLong; Thinzar M Lwin; Takashi Chishima; Kuniya Tanaka; Michael Bouvet; Itaru Endo; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2017-03-15       Impact factor: 4.534

9.  Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Shukuan Li; Qinghong Han; Yuying Tan; Ming Zhao; Yunfeng Li; Scott D Nelson; Sarah M Dry; Arun S Singh; Irmina A Elliott; Tara A Russell; Mark A Eckardt; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Hiroyuki Tsuchiya; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-04-10       Impact factor: 4.534

10.  Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients.

Authors:  Kei Kawaguchi; Kentaro Igarashi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Takashi Murakami; Bartosz Chmielowski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Arun S Singh; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-03-29       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.